1 | 10146 | LAO-CT018 | ETCTN | Breast Cancer | Active | Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients with Metastatic Triple Negative Breast Cancer | II | 27/70 | N/A | INTERVENTION |
2 | 10222 | LAO-CT018 | ETCTN | Gastrointestinal Cancer;Solid Tumor | Temporarily Closed to Accrual | A Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH) Mutant Solid Tumors | II | 24/50 | N/A | INTERVENTION |
3 | 10273 | LAO-CA043 | ETCTN | Leukemia | Active | A Phase I Study of M3814 in Combination with MEC in Patients with Relapsed or Refractory Acute Myeloid Leukemia | I | 25/48 | N/A | INTERVENTION |
4 | 10292 | LAO-NCI | ETCTN | Solid Tumor | Active | DURVA+ : Evaluation of the Safety and Pharmacodynamics of Anti-PD-L1 Antibody Durvalumab in Combination with Chemotherapy in Patients with Advanced Solid Tumors | II | 74/115 | N/A | INTERVENTION |
5 | 10330 | LAO-CT018 | ETCTN | Bone Cancer | Temporarily Closed to Accrual | A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma | II | 19/32 | N/A | INTERVENTION |
6 | 10504 | LAO-NCI | ETCTN | Soft Tissue Cancer/Sarcoma | Active | A Randomized Phase 2 Study of Atezolizumab with or Without Selinexor in Alveolar Soft Part Sarcoma (AXIOM) | II | 8/77 | N/A | INTERVENTION |
7 | 10507 | LAO-MA036 | ETCTN | Miscellaneous and Metastatic Cancer | Active | A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination with Etoposide/Platinum in Patients with NUT Carcinoma | I/II | 12/18 | N/A | INTERVENTION |
8 | 10579 | LAO-PA015 | ETCTN | Gastrointestinal Cancer;Solid Tumor | Active | Phase I Trial of ZEN003694 (ZEN-3694) in Combination with Capecitabine in Patients with Solid Tumors | I | 4/30 | N/A | INTERVENTION |
9 | 10603 | LAO-MA036 | ETCTN | Male Reproductive System Cancer | Active | A Phase 2 Study of M1774 in Refractory SPOP-Mutant Prostate Cancer | II | 2/17 | N/A | INTERVENTION |
10 | 10612 | LAO-CT018 | ETCTN | Myeloma | Active | A Randomized Phase 2 Study of Daratumumab-Selinexor-Velcade-Dexamethasone (Dara-SVD) for High-Risk Newly Diagnosed Multiple Myeloma | II | 0/70 | N/A | INTERVENTION |
11 | A021806 | ALLIANCE | NCTN | Gastrointestinal Cancer | Active | A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer | III | 248/352 | N/A | INTERVENTION |
12 | A021901 | ALLIANCE | NCTN | Endocrine Cancer | Active | Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors | II | 13/108 | N/A | INTERVENTION |
13 | A032103 | ALLIANCE | NCTN | Urothelial/ Bladder Cancer | Active | MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer | III | N/A | 4 | SCREENING |
14 | A041703 | ALLIANCE | NCTN | Leukemia | Active | A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults with Relapsed or Refractory Disease | II | 59/64 | N/A | INTERVENTION |
15 | A051902 | ALLIANCE | NCTN | Lymphoma | Active | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | II | 41/182 | N/A | INTERVENTION |
16 | A071401 | ALLIANCE | NCTN | CNS Cancer (Primary tumor) | Active | Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2/CDK Pathway Mutations | II | 89/124 | 465 | SCREENING, INTERVENTION |
17 | A091903 | ALLIANCE | NCTN | Skin Cancer | Active | A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma | II | 28/99 | N/A | INTERVENTION |
18 | A092105 | ALLIANCE | NCTN | Head and Neck Cancer | Active | Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy | II | 1/50 | N/A | INTERVENTION |
19 | A211801 | ALLIANCE | NCORP | N/A | Active | BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation | III | 28/300 | N/A | INTERVENTION |
20 | A212102 | ALLIANCE | NCORP | Miscellaneous and Metastatic Cancer | Active | Blinded Reference Set For Multicancer Early Detection Blood Tests | Other | N/A | N/A | OTHER |
21 | ACCL1931 | COG | NCORP | Miscellaneous and Metastatic Cancer | Active | A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy | III | 29/440 | N/A | INTERVENTION |
22 | AMC-112 | AMC | MISCELLANEOUS | AIDS-related Malignancy and Condition | Temporarily Closed to Accrual | Axicabtagene Ciloleucel in Relapsed or Refractory HIV-Associated Aggressive B-Cell Non-Hodgkin Lymphoma | I | 0/20 | 0 | SCREENING, INTERVENTION |
23 | AOST2032 | COG | NCTN | Bone Cancer | Temporarily Closed to Accrual | A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma | II/III | 10/528 | N/A | INTERVENTION |
24 | DCP-001 | DCP | NCORP | Hematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Solid Tumor | Active | Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) | Other | N/A | N/A | OTHER |
25 | EA1211 | ECOG-ACRIN | NCTN | Breast Cancer | Active | Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT Trial | II | 23/235 | N/A | INTERVENTION |
26 | EA2174 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Temporarily Closed to Accrual | A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma | II/III | 275/278 | N/A | INTERVENTION |
27 | EA2176 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | A Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients | III | 172/205 | N/A | INTERVENTION |
28 | EA2192 | ECOG-ACRIN | NCTN | Gastrointestinal Cancer | Active | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | II | 57/152 | N/A | INTERVENTION |
29 | EA6141 | ECOG-ACRIN | NCTN | Skin Cancer | Active | Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma | II/III | 471/601 | N/A | INTERVENTION |
30 | EA8134 | ECOG-ACRIN | NCTN | Male Reproductive System Cancer | Active | InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | III | 89/200 | N/A | INTERVENTION |
31 | EA8192 | ECOG-ACRIN | NCTN | Urothelial/ Bladder Cancer | Active | A Phase II/III Trial of Durvalumab and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy | II/III | 38/249 | N/A | INTERVENTION |
32 | EA8212 | ECOG-ACRIN | NCTN | Urothelial/ Bladder Cancer | Active | A Randomized Phase III Trial of Intravesical BCG VeRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE) | III | 334/870 | N/A | INTERVENTION |
33 | EAA173 | ECOG-ACRIN | NCTN | Myeloma | Active | Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) | III | 163/288 | N/A | INTERVENTION |
34 | EAQ211 | ECOG-ACRIN | NCORP | Lymphoma | Active | Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma | Other | N/A | N/A | OTHER |
35 | EAY191 | ECOG-ACRIN | NCTN | Lymphoma;Solid Tumor | Active | Molecular Analysis for Combination Therapy Choice (ComboMATCH) | Other | N/A | 113 | SCREENING |
36 | EAY191-N5 | NRG | NCTN | Bone Cancer;CNS Cancer (Primary tumor);Endocrine Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Germ Cell Cancer;Head and Neck Cancer;Kidney Cancer;Lung, Mediastinal, and Pleural Cancer;Male Reproductive System Cancer;Miscellaneous and Metastatic Cancer;Skin Cancer;Soft Tissue Cancer/Sarcoma;Solid Tumor;Urothelial/ Bladder Cancer | Active | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial | II | 0/70 | N/A | INTERVENTION |
37 | NRG-BR008 | NRG | NCTN | Breast Cancer | Active | A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO) | III | 18/1300 | N/A | INTERVENTION |
38 | NRG-GU012 | NRG | NCTN | Kidney Cancer | Active | Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI) | II | 16/240 | N/A | INTERVENTION |
39 | NRG-GY022 | NRG | NCTN | Solid Tumor | Active | Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin | I | 266/350 | N/A | INTERVENTION |
40 | PBTC-061 | PBTC | MISCELLANEOUS | CNS Cancer (Primary tumor) | Active | Phase 2 Trial of G207 + 5 Gy Radiation for Children with High-Grade Gliomas | II | 0/35 | N/A | INTERVENTION |
41 | S1914 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC | III | 333/480 | N/A | INTERVENTION |
42 | S1933 | SWOG | NCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status | II | 35/47 | N/A | INTERVENTION |
43 | S2012 | SWOG | NCTN | Endocrine Cancer | Active | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or Without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) | II/III | 40/189 | N/A | INTERVENTION |
44 | S2013 | SWOG | NCORP | N/A | Active | Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study | Other | N/A | N/A | OTHER |
45 | S2207 | SWOG | NCTN | Lymphoma | Active | Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma | II | 7/227 | N/A | INTERVENTION |
46 | S2209 | SWOG | NCTN | Myeloma | Active | A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of "Intermediate Fit" Comparing Upfront Three-Drug Induction Regimens Followed by Double or Single-Agent Maintenance | III | 16/510 | N/A | INTERVENTION |
47 | 10323 | DCTD | NCI | Breast Cancer;Female Reproductive System Cancer;Gastrointestinal Cancer;Leukemia;Lung, Mediastinal, and Pleural Cancer;Male Reproductive System Cancer;Myeloma;Skin Cancer | Active | Cancer Moonshot Biobank Research Protocol | Other | N/A | N/A | OTHER |
48 | 10324 | LAO-MD017 | ETCTN | Female Reproductive System Cancer | Active | A Phase I/Ib Dose Escalation Study of Pegylated Liposomal Doxorubicin (PLD) with Peposertib (M3814) in Platinum - Resistant or Ineligible Ovarian and Related Cancers with Planned Expansions in High Grade Serous (HGSOC) and Low Grade Serous Ovarian Cancer (LGSOC) | I | 51/49 | N/A | INTERVENTION |
49 | 10327 | LAO-CA043 | ETCTN | Lung, Mediastinal, and Pleural Cancer | Active | A Phase I Trial of MLN0128 (Sapanisertib) and Telaglenastat (CB-839) HCL in Advanced NSCLC Patients | I | 18/85 | N/A | INTERVENTION |
50 | 10335 | LAO-CT018 | ETCTN | Leukemia;Lymphoma | Active | A Phase 1 Study of Lenalidomide in Combination with EPOCH Chemotherapy for HTLV-Associated Adult T-Cell Leukemia-Lymphoma (ATLL) | I | 10/30 | N/A | INTERVENTION |